<DOC>
	<DOCNO>NCT00438607</DOCNO>
	<brief_summary>The main purpose study determine safety BIIB014 well BIIB014 tolerate give different dos patient moderate late-stage Parkinson 's Disease also take Parkinson 's medication , levodopa ( L-DOPA ) . This study also explore : 1. pharmacokinetics BIIB014 Parkinson 's patient also take L-DOPA ( do measuring level BIIB014 blood several different time study ) , 2. activity BIIB014 give Parkinson 's patient also take L-DOPA ( do perform different Parkinson 's Disease assessment study examine change wake OFF time , change time troublesome dyskinesia , change Unified PD Rating Scale ( UPDRS ) score , Clinical Global Improvement ) . Patients enter study randomly assign receive either BIIB014 placebo study blind , neither study doctor know study treatment take . The study divide 2 part : - Part A : , rapid , sequential cohort , dose escalation establish MTD , follow - Part B : parallel-group exploration two high tolerate dos versus placebo . Note : As Part A study conclude , study design information present ( e.g. , number study arm ) pertain Part B .</brief_summary>
	<brief_title>Dose-Finding Safety Study BIIB014 Combination With Levodopa Moderate Late Stage Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>3- ( 4-amino-3-methylbenzyl ) -7- ( 2-furyl ) -3H- ( 1,2,3 ) triazolo ( 4,5-d ) pyrimidine-5-amine</mesh_term>
	<criteria>Must carry diagnosis idiopathic PD accord UK Parkinson 's Disease Society Brain Bank Clinical Diagnostic Criteria , Hoehn &amp; Yahr Stage II IV ( inclusive ) OFF . Must stable dose L3,4dihydroxyphenylalanine ( LDOPA ) /carbidopa LDOPA/benserazide least 4 week prior enrollment . Except LDOPA certain allow dopamine agonist , must receive PD medication . ( Current treatment certain dopamine agonist allow subject must stable dose least 4 week prior enrollment ) . Some subject must demonstrate definite end LDOPA dose wear ( least 2 hour OFF time per wake day ) must able keep accurate patient diary PD activity . Major A Mini Mental State Examination ( MMSE ) score &lt; 26 . History clinical feature consistent atypical parkinsonian syndrome . Any significant nonParkinson 's central nervous system disorder . Any significant AXIS I psychiatric disease Diagnostic Statistical Manual Mental Disorders ( DSM ) . Any previous surgical intervention Parkinson 's Disease . History certain malignancy . History severe allergic anaphylactic reaction drug . Clinically significant baseline electrocardiogram ( ECG ) . Orthostatic hypotension . HbA1c &gt; 7.0 %</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Moderate late stage Parkinson 's Disease</keyword>
</DOC>